Larsson P G, Haffner F, Brłnstad G O, Christoffersen T
Br J Cancer. 1979 Nov;40(5):768-73. doi: 10.1038/bjc.1979.259.
The antitumour agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC) was found to inhibit competitively the low-Km cyclic AMP phosphodiesterase activity in an ammonium-sulphate-precipitable fraction of the 2,000g supernatant of rat liver. With substrate concentration at 0.25 microM, I50 was 790 microM for DTIC and 350 microM for theophylline. DTIC at 2 mM more than doubled the cAMP response to glucagon in hepatocytes and to adrenaline in MH1C1 hepatoma cells, indicating that it also exerts its inhibitory effect on the phosphodiesterase in intact cells. The possible contribution of the phosphodiesterase inhibition to the growth-inhibitory and cytotoxic effects of DTIC is discussed.
抗肿瘤药物5-(3,3-二甲基-1-三氮烯)咪唑-4-甲酰胺(DTIC)被发现可竞争性抑制大鼠肝脏2000g上清液硫酸铵沉淀部分中的低Km环磷酸腺苷磷酸二酯酶活性。底物浓度为0.25微摩尔时,DTIC的半数抑制浓度(I50)为790微摩尔,茶碱的I50为350微摩尔。2毫摩尔的DTIC使肝细胞中对胰高血糖素以及MH1C1肝癌细胞中对肾上腺素的环磷酸腺苷反应增加了一倍多,这表明它对完整细胞中的磷酸二酯酶也有抑制作用。本文讨论了磷酸二酯酶抑制作用对DTIC的生长抑制和细胞毒性作用可能的贡献。